FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of August
2019
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
19 August 2019 07:00 BST
AstraZeneca appoints Michel Demaré to its Board of
Directors
AstraZeneca today announced that, with effect from 1 September
2019, Michel Demaré is appointed as a Non-Executive Director
and a member of the Audit Committee.
Leif Johansson, Chairman of AstraZeneca, said: "We are delighted to
appoint Michel Demaré as a Director. He has a great deal of
industrial, financial and board-level experience across a range of
sectors including science and technology, that will enable him to
contribute well to the work of our Board and Audit
Committee."
Michel Demaré is a Non-Executive Director of Vodafone Group
Plc and a member of the Supervisory Board of Louis Dreyfus Company
Holdings BV. He is Vice-Chairman and Chairman-designate of the IMD
executive business school in Lausanne, and a member of the Advisory
Board of the Department of Banking and Finance at the University of
Zurich.
Mr Demaré was Vice-Chairman of UBS Group AG from 2010 to 2019,
Chairman of Syngenta and the Syngenta Foundation for Sustainable
Agriculture from 2013 to 2017 and Chairman of SwissHoldings from
2013 to 2015.
Mr Demaré joined ABB Ltd in 2005 as Chief Financial Officer
(CFO) and member of the Group Executive Committee. For most
of 2008, he acted as the interim Chief Executive Officer of
ABB. From late 2008 to 2011, he combined his role as CFO with
that of President of Global Markets.
He joined ABB from Baxter International Inc., where he was CFO
Europe from 2002 to 2005. Prior to that, he spent 18 years at
the Dow Chemical Company, holding various treasury and risk
management positions in Belgium, France, the US and
Switzerland. Between 1997 and 2002, Mr Demaré was CFO of
the Global Polyolefins and Elastomers division. He began his
career as a banking officer in the multinational banking division
of Continental Illinois' Belgian subsidiary.
Mr Demaré graduated with an MBA from the Katholieke
Universiteit Leuven, Belgium, and holds a degree in applied
economics from the Université Catholique de Louvain,
Belgium.
Except as set out above, no disclosure obligations arise under
paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's
Listing Rules in respect of this appointment.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203 749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203 749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301 518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203 749 5906
|
|
Jennifer
Hursit
|
Other
|
+44 203 749 5762
|
|
Christina
Malmberg Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals (cardiovascular, metabolism)
|
+44 203 749 5711
|
|
Nick
Stone
|
BioPharmaceuticals (respiratory, renal)
|
+44 203 749 5716
|
|
Josie
Afolabi
|
Other medicines
|
+44 203 749 5631
|
|
Craig
Marks
|
Finance, fixed income
|
+44 7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate access, retail investors
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
19 August 2019
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|